VistaGen Therapeutics

Yahoo Finance • 2 years ago

Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., September 09, 2022--(BUSINESS WIRE)--Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua... Full story

Yahoo Finance • 2 years ago

2 “Strong Buy” Penny Stocks That Could Go Boom

Between the Fed's aggressive policy tightening to rein in inflation and deteriorating economic data, volatility has become a seemingly ever-present facet of the stock market. While the current economic landscape has spurred fear among inve... Full story

Yahoo Finance • 3 years ago

VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update

Completed last patient out milestone for PALISADE-1 Phase 3 clinical trial of PH94B in social anxiety disorder (SAD). Topline results for PALISADE-1 anticipated mid-2022. PALISADE-2 on track for topline readout in late 2022. Received FDA c... Full story